ExonHit Eyes Affy Platform for Alzheimer’s Test; Could Launch Dx As Early As 2009

Until now, ExonHit has shied from discussing which platform it deems the most suitable for commercializing the multiplex test. A company official said the firm is still evaluating options for the Alzheimer’s test, though it has a positive view of the Affy platform.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.